Filter your search
Infectious DiseaseX
Infectious disease tests are one of the most dynamic spaces in the in vitro diagnostics (IVD) industry. Global market growth is a product of new disease threats as well as the introduction and clinical acceptance of routine screening procedures. The diversified market space promotes demand for novel diagnostic technologies such as PCR-alternative molecular amplification methods, next-generation sequencing (NGS), and mass spectrometry. The $17 billion+ global infectious disease diagnostics market also includes larger established segments in immunoassays and ID/AST.
- $150.00 – $300.00A hospital-acquired infection (HAI)is a new infection that develops in a patient during hospitalization. It is usually defined as an infection that is identified at least forty-eight to seventy-two hours following admission, so infections incubating, but not clinically apparent, at admission are excluded. This type of infection is also known as a nosocomial infection (or […]July 1, 2011$250.00 – $1,600.00The outbreak of H1N1 (swine flu) highlighted the public health importance of improved testing techniques and providing market opportunities for manufacturers of diagnostic tests and other products related to the disease. These conclusions and others appear in a new report released from Kalorama Information: Swine Flu Market Alert by Kalorama’s lead analyst, Shara Rosen. Regardless […]May 1, 2009$1,500.00 – $7,000.00Test services, once the norm in the diagnostics industry, then abandoned for reagent sales, are now making a comeback. IVD companies have established cGMP and CLIA-registered labs by which they offer their proprietary tests to physicians, hospitals and reference labs. These tests are outside the oversight of the traditional FDA and CE Mark test commercialization […]August 1, 2008$995.00 – $1,990.00Currently, the largest market application segment for molecular diagnostics is that for infectious disease testing. The segment is expected to grow at an annual rate between 7% and 8% over the next few years will present some excellent market opportunites for molecular diagnostic competitors. This summary report, extracted from Kalorama Information’s U.S. Market for Molecular […]October 1, 2004